Cardinal Health Inc (CAH) Q2 2025 Earnings Call Highlights: Strong Pharma Growth Amid Revenue ...
Cardinal Health Inc (CAH) raises EPS guidance despite a 4% revenue decline, driven by robust pharmaceutical segment performance and strategic acquisitions.
Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript
Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is being recorded.
Cardinal Health Inc Q2 Profit Increases, Beats Estimates
Cardinal Health Inc (CAH) revealed a profit for its second quarter that increased from last year and beat the Street estimates. The
Here's Why Cardinal Health (CAH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal: Fiscal Q2 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.75 per share. The prescription drug distributor posted revenue of $55.26 billion in the period, also topping Street forecasts.
Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Cardinal Health (CAH) reported $55.26 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 3.8%. EPS of $1.93 for the same period compares to $1.82 a year ago.
Cardinal Health’s Strong Performance and Strategic Acquisitions Justify Buy Rating
Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday.Invest with ...
Cardinal Health raises FY25 EPS guidance to $7.85-$8 amid specialty growth and acquisitions
Q2 2025 Management View CEO Jason Hollar emphasized strong Q2 performance driven by robust demand in Pharmaceutical and ...
Cardinal Health lifts 2025 profit forecast on specialty drugs demand
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Positive Financial Prospects Drive Buy Rating for Cardinal Health Amid Raised Guidance and Strong Segment Performance
Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on Cardinal Health (CAH – Research Report). The associated price target was ...
Modern Healthcare15h
Cardinal Health CEO Jason Hollar issues warning on tariffs
Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...
Cardinal Health may raise prices to offset potential tariffs
By Christy Santhosh and Kamal Choudhury (Reuters) -Drug distributor Cardinal Health said on Thursday it may need to increase prices of some of its products if the proposed tariffs on Mexico go into ...
Drug Store News18h
Cardinal Health reports Q2 results, raises fiscal year 2025 outlook
Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.
Cardinal Health Inc. stock underperforms Tuesday when compared to competitors
Cardinal Health Inc. closed 2.50% below its 52-week high of $131.00, which the company reached on January 27th.
Hoodline15h
Dublin City Schools Abandons Cardinal Health Building Purchase, Opts for Scioto High School Expansion
Dublin City Schools has officially backed out of a deal to acquire the vacant Cardinal Health office building, pivoting ...
Citi raises Cardinal Health stock target to $130 on Pharma strength
Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows ...